Enwei Pharmaceutical Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Enwei Pharmaceutical Co., Ltd.

Why is Enwei Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 9.53% and Operating profit at -13.12% over the last 5 years

Flat results in Sep 25

INTEREST(HY) At CNY 1.42 MM has Grown at 6.89%
OPERATING PROFIT(Q) Lowest at CNY -4.7 MM
OPERATING PROFIT MARGIN(Q) Lowest at -2.51 %

With ROE of 5.35%, it has a attractive valuation with a 2.96 Price to Book Value

Over the past year, while the stock has generated a return of 0.28%, its profits have risen by 43.8% ; the PEG ratio of the company is 1.3

Underperformed the market in the last 1 year

The stock has generated a return of 0.28% in the last 1 year, much lower than market (China Shanghai Composite) returns of 15.45%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Enwei Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Enwei Pharmaceutical Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Enwei Pharmaceutical Co., Ltd.

2.88%

-0.18

41.22%

China Shanghai Composite

15.45%

1.03

14.98%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.53%

EBIT Growth (5y)

-13.12%

EBIT to Interest (avg)

53.36

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.30

Sales to Capital Employed (avg)

0.67

Tax Ratio

16.24%

Dividend Payout Ratio

47.00%

Pledged Shares

Institutional Holding

ROCE (avg)

9.58%

ROE (avg)

5.60%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.96

EV to EBIT

44.00

EV to EBITDA

24.74

EV to Capital Employed

3.86

EV to Sales

3.31

PEG Ratio

1.26

Dividend Yield

ROCE (Latest)

8.78%

ROE (Latest)

5.35%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

NET PROFIT(HY)

At CNY 20.28 MM has Grown at 49.14%

RAW MATERIAL COST(Y)

Fallen by -3.32% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 4.29 times

DEBTORS TURNOVER RATIO(HY)

Highest at 3.54 times

DIVIDEND PER SHARE(HY)

Highest at CNY 3.54

-17What is not working for the Company

INTEREST(HY)

At CNY 1.42 MM has Grown at 6.89%

OPERATING PROFIT(Q)

Lowest at CNY -4.7 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -2.51 %

PRE-TAX PROFIT(Q)

Lowest at CNY -2.54 MM

NET PROFIT(Q)

Lowest at CNY -1.76 MM

EPS(Q)

Lowest at CNY -0.02

Here's what is working for Enwei Pharmaceutical Co., Ltd.

Inventory Turnover Ratio

Highest at 4.29 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 3.54 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Dividend per share

Highest at CNY 3.54

in the last five years

MOJO Watch

Company is distributing higher dividend from profits generated

DPS (CNY)

Raw Material Cost

Fallen by -3.32% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Enwei Pharmaceutical Co., Ltd.

Pre-Tax Profit

At CNY -2.54 MM has Fallen at -196.49%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Profit

At CNY -1.76 MM has Fallen at -143.05%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Interest

At CNY 1.42 MM has Grown at 6.89%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Operating Profit

Lowest at CNY -4.7 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at -2.51 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at CNY -2.54 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit

Lowest at CNY -1.76 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

EPS

Lowest at CNY -0.02

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CNY)